Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

被引：0
|
作者：
Ninh M. La-Beck
Beth A. Zamboni
Alberto Gabizon
Hilary Schmeeda
Michael Amantea
Paola A. Gehrig
William C. Zamboni
机构：
[1] University of North Carolina at Chapel Hill,UNC Eshelman School of Pharmacy
[2] Texas Tech University Health Sciences Center,Center for Immunotherapeutic Research and Department of Pharmacy Practice, School of Pharmacy
[3] Carlow University,Department of Mathematics
[4] Shaare Zedek Medical Center and Hebrew University-School of Medicine,Department of Oncology
[5] Pfizer,Department of Clinical Pharmacology
[6] Inc.,Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine
[7] University of North Carolina at Chapel Hill,Molecular Therapeutics, Lineberger Comprehensive Cancer Center
[8] University of North Carolina at Chapel Hill,Institute for Pharmacogenomics and Individualized Therapy
[9] University of North Carolina at Chapel Hill,Carolina Center of Cancer Nanotechnology Excellence
[10] University of North Carolina at Chapel Hill,Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy
[11] University of North Carolina at Chapel Hill,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Doxil; Liposomal; Pharmacokinetics; Variability; Monocytes; Reticuloendothelial system; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [11] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Zhen Yuan
    Ying Zhang
    Dongyan Cao
    Keng Shen
    Qingshui Li
    Guonan Zhang
    Xiaohua Wu
    Manhua Cui
    Ying Yue
    Wenjun Cheng
    Li Wang
    Pengpeng Qu
    Guangshi Tao
    Jianqing Hou
    Lixin Sun
    Yuanguang Meng
    Guiling Li
    Changzhong Li
    Huirong Shi
    Yaqing Chen
    Journal of Ovarian Research, 14
  • [12] Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer
    David S. Alberts
    Dava J. Garcia
    Drugs, 1997, 54 : 30 - 35
  • [13] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [14] Safety aspects of pegylated liposomal doxorubicin in patients with cancer
    Alberts, DS
    Garcia, DJ
    DRUGS, 1997, 54 (Suppl 4) : 30 - 35
  • [15] Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs
    Song, Gina
    Wu, Huali
    Yoshino, Keisuke
    Zamboni, William C.
    JOURNAL OF LIPOSOME RESEARCH, 2012, 22 (03) : 177 - 192
  • [16] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®)
    Boers-Sonderen, Marye J.
    van Herpen, Carla M. L.
    van der Graaf, Winette T. A.
    Desar, Ingrid M. E.
    Arens-van der Logt, Mirjam G. W.
    de Beer, Yvo M.
    Ottevanger, Petronella B.
    van Erp, Nielka P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 457 - 463
  • [17] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)
    Marye J. Boers-Sonderen
    Carla M. L. van Herpen
    Winette T. A. van der Graaf
    Ingrid M. E. Desar
    Mirjam G. W. Arens- van der Logt
    Yvo M. de Beer
    Petronella B. Ottevanger
    Nielka P. van Erp
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 457 - 463
  • [18] Monocytes Do Not Contribute to Sex Differences Seen in the Pharmacokinetics of Pegylated Liposomal Doxorubicin
    Wang, Lili
    Butcher, Neville J.
    Minchin, Rodney F.
    Kaminskas, Lisa M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (08) : 3099 - 3101
  • [19] Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
    Wu, Huali
    Infante, Jeffrey R.
    Jones, Suzanne F.
    Burris, Howard A., III
    Chan, Emily
    Keedy, Vicki L.
    Bendell, Johanna C.
    Zamboni, Beth A.
    Kodaira, Hiroshi
    Ikeda, Satoshi
    Zamboni, William C.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [20] A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
    von Mehren, M.
    Schilder, R. J.
    Cheng, J. D.
    Temmer, E.
    Cardoso, T. M.
    Renshaw, F. G.
    Bayever, E.
    Zannikos, P.
    Yuan, Z.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1802 - 1809
12345